Company: JUNS
Filing Date: 2025-08-19
Form Type: 10-Q
Source: 0001641172-25-024684
Chunk: 19

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-08-19
Form: 10-Q
Item: Item 8
Chunk 19
---
12 months later. The Company
also aims to explore other CNS indications, such as Mild Cognitive Impairment (“MCI”) and Alzheimer’s disease, following
the Parkinson’s study

The
Company believes, based on pre-clinical and clinical studies, that high doses of resveratrol are necessary for therapeutic effects. Current
resveratrol products can not reach these levels without causing severe gastrointestinal side effects. Indications are from human studies
in Alzheimer’s patients (Turner et al 2015) and Friedreich’s Ataxia patients (Yu et al 2015) that a concentration at the highest dose
(CMax) of resveratrol in blood plasma needs to be 200 ng/ml or higher for therapeutic effect. A Phase 1 study with 500mg of resveratrol
as a maximum dose in the JOTROL formulation showed levels of resveratrol exceeding 800 ng/ml without generating any severe adverse events (AAPS
Open 2022). Resveratrol was shown in the Turner Alzheimer’s study to cross the blood-brain barrier, indicating positive effects
on oxidative stress and inflammation. Subsequent analysis published in Molecular Science 2025 (Mousa et al) further indicates that resveratrol
has effect on neurodegeneration and neuroinflammation in Alzheimer’s patients.

Over
the past two years, JOTROL has garnered significant interest from Asian organizations. This interest is partly due to resveratrol’s use
in Asian herbal medicines, recent patent approvals in Hong Kong and China, and China’s list of rare disease indications where JOTROL
could be applicable. Additionally, recent publications in the Journal of Alzheimer’s Disease and AAPS Open, along with the projected
growth of the Traditional Chinese Medicine market, have contributed to this interest.

The
Company has entered service agreements with firms in Hong Kong to accelerate product development in South-East Asia. These agreements
aim to leverage local expertise and networks to facilitate market entry and potential out-licensing deals. The Company entered into an
agreement with Dominant Treasure Health to expand its business development in China, Malaysia, and Singapore, aiming to penetrate the
large and challenging Asian market.

23

In
March 2025, the Company announced that it had entered into a partnership with Aquanova AG to develop a series of nutritional products
targeting longevity, aging and healthspan. The first three products, which will focus on the concept of “Beauty